Mean daily rating of problem severity (lower score is better) · women with premenstrual syndrome (most met DSM‐V criteria for premenstrual dysphoric disorder (PMDD))
1 finding from 1 review
Mean change in daily rating of functional impairment: reduction of productivity (lower score is better) · women with premenstrual syndrome (most met DSM‐V criteria for premenstrual dysphoric disorder (PMDD))
1 finding from 1 review
Mean change in daily rating of functional impairment: social activities (lower score is better) · women with premenstrual syndrome (most met DSM‐V criteria for premenstrual dysphoric disorder (PMDD))
1 finding from 1 review
Mean change in daily rating of functional impairment: relationship interference (lower score is better) · women with premenstrual syndrome (most met DSM‐V criteria for premenstrual dysphoric disorder (PMDD))
1 finding from 1 review
Withdrawals due to adverse events · women with premenstrual syndrome (most met DSM‐V criteria for premenstrual dysphoric disorder (PMDD))
Drospirenone plus ethinylestradiol may leads to higher withdrawal due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Time (days) to achieve exclusive oral feeding · preterm infants
1 finding from 1 review
Time (days) spent in NICU ‐ not reported · preterm infants
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Length of hospital stay · preterm infants
1 finding from 1 review
Duration (days) of parenteral nutrition ‐ not reported · preterm infants
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time (days) to achieve exclusive oral feeding · preterm infants
1 finding from 1 review
Time (days) spent in NICU ‐ not reported · preterm infants
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Length of hospital stay · preterm infants
1 finding from 1 review
Duration (days) of parenteral nutrition · preterm infants
1 finding from 1 review
Death or bronchopulmonary dysplasia at 36 weeks PMA · preterm infants at risk for bronchopulmonary dysplasia
Lower showed no clear difference in death or bronchopulmonary dysplasia at 36 weeks PMA compared with higher cumulative dose dexamethasone regimen (low certainty).
1 finding from 1 review
Death or cerebral palsy at 1 to 3 years · preterm infants at risk for bronchopulmonary dysplasia
Individual tailored showed no clear difference in death or cerebral palsy at 1 to 3 years compared with continuous tapered dexamethasone regimen (moderate certainty).
1 finding from 1 review
Death or abnormal neurodevelopmental outcome (various definitions) · preterm infants at risk for bronchopulmonary dysplasia
Individual tailored showed no clear difference in death or abnormal neurodevelopmental outcome (various definitions) compared with continuous tapered dexamethasone regimen (low certainty).
1 finding from 1 review
Death or cerebral palsy at 1 to 3 years · preterm infants at risk for bronchopulmonary dysplasia
Lower showed no clear difference in death or cerebral palsy at 1 to 3 years compared with higher cumulative dose dexamethasone regimen (low certainty).
1 finding from 1 review
Death or abnormal neurodevelopmental outcome (various definitions) · preterm infants at risk for bronchopulmonary dysplasia
It is very uncertain whether lower changes death or abnormal neurodevelopmental outcome (various definitions)… compared with higher cumulative dose dexamethasone regimen (very low certainty).
1 finding from 1 review
Death or bronchopulmonary dysplasia at 36 weeks PMA · preterm infants at risk for bronchopulmonary dysplasia
Later showed no clear difference in death or bronchopulmonary dysplasia at 36 weeks' PMA compared with earlier initiation of dexamethasone therapy (low certainty).
1 finding from 1 review
Death or cerebral palsy at 1 to 3 years · preterm infants at risk for bronchopulmonary dysplasia
Later showed no clear difference in death or cerebral palsy at 1 to 3 years compared with earlier initiation of dexamethasone therapy (low certainty).
1 finding from 1 review